These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26982103)

  • 21. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
    J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
    Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tigecycline : a critical safety review.
    Kaewpoowat Q; Ostrosky-Zeichner L
    Expert Opin Drug Saf; 2015 Feb; 14(2):335-42. PubMed ID: 25539800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii.
    Liu B; Bai Y; Liu Y; Di X; Zhang X; Wang R; Wang J
    J Chemother; 2015 Oct; 27(5):271-6. PubMed ID: 25068186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ; Goff DA
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii.
    Dinc G; Demiraslan H; Elmali F; Ahmed SS; Alp E; Doganay M
    New Microbiol; 2015 Jan; 38(1):67-73. PubMed ID: 25742149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline.
    Falagas ME; Karageorgopoulos DE; Dimopoulos G
    Curr Drug Metab; 2009 Jan; 10(1):13-21. PubMed ID: 19149509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections.
    Liebenstein T; Schulz LT; Viesselmann C; Bingen E; Musuuza J; Safdar N; Rose WE
    Pharmacotherapy; 2017 Feb; 37(2):151-158. PubMed ID: 27983753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of tigecycline: a systematic review and meta-analysis.
    Yahav D; Lador A; Paul M; Leibovici L
    J Antimicrob Chemother; 2011 Sep; 66(9):1963-71. PubMed ID: 21685488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tigecycline: a review of a new glycylcycline antibiotic.
    Scheinfeld N
    J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline.
    Pankey GA
    J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections.
    Wilcox MH
    J Chemother; 2005 Aug; 17 Suppl 1():23-9. PubMed ID: 16285355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of tigecycline in the treatment of infections in light of the new black box warning.
    Dixit D; Madduri RP; Sharma R
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):397-400. PubMed ID: 24597542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tigecycline: a new glycylcycline antimicrobial agent.
    Kasbekar N
    Am J Health Syst Pharm; 2006 Jul; 63(13):1235-43. PubMed ID: 16790575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of tigecycline and its role in the era of antibiotic resistance.
    Rossi F; Andreazzi D
    Braz J Infect Dis; 2006 Jun; 10(3):203-16. PubMed ID: 17568854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of tigecycline--the first glycylcycline.
    Peterson LR
    Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S215-22. PubMed ID: 19134522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New antibiotic agents: problems and prospects.
    Weber DJ; Rutala WA
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-97-107. PubMed ID: 23577500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.
    Tasina E; Haidich AB; Kokkali S; Arvanitidou M
    Lancet Infect Dis; 2011 Nov; 11(11):834-44. PubMed ID: 21784708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.